Adecto is a pre-clinical stage, cancer therapeutics company, developing the first targeted therapy against ADAM8-expressing cancers and a companion diagnostic to identify patients who can benefit from it. ADAM8 is a critical driver of the growth and spread of many aggressive tumors, including those of the breast, stomach, colon, lungs, liver and pancreas, and is associated with poor patient survival. Adecto’s current focus is on breast cancer with a plan to expand to other oncology indications in the future. If you are interested in learning more, please visit us at www.adectopharma.com
Company Details
- Employees
- 6
- Founded
- 2014
- Address
- 75 Kneeland Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- adectopharma.com
- Keywords
- Beverly.
- HQ
- Boston, MA
Adecto Pharmaceuticals Questions
Adecto Pharmaceuticals's website is adectopharma.com
Adecto Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/adecto-pharmaceuticals
Adecto Pharmaceuticals has
6 employees.
View email and phone details for 6
employees at Adecto Pharmaceuticals.
Adecto Pharmaceuticals's industry is
Biotechnology Research
Adecto Pharmaceuticals's top competitors are
Lunatum Biotech,
Genomic Expression Inc,
Finch Therapeutics,
Artificial Axon Labs,
Axonis Therapeutics,
Vanda Pharmaceuticals,
Thetis Pharmaceuticals,
Harbour Biomed,
Centessa Pharmaceuticals,
Phagepro.
Adecto Pharmaceuticals's categories are Biotechnology Research
Adecto Pharmaceuticals's founding year is 2014
